Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice

Kazunori Shibuya, Tomoaki Kuwaki, Hiromichi Akahori, Takashi Kato, Hiroshi Miyazaki

    Research output: Contribution to journalArticle

    1 Citation (Scopus)

    Abstract

    We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.

    Original languageEnglish
    Pages (from-to)941-946
    Number of pages6
    JournalLeukemia Research
    Volume28
    Issue number9
    DOIs
    Publication statusPublished - 2004 Sep

      Fingerprint

    Keywords

    • acute myelogenous leukemia
    • AML
    • bovine serum albumin
    • BSA
    • FCS
    • fetal calf serum
    • L-CFU
    • leukemia colony-forming unit
    • PEG-rHuMGDF
    • pegylated recombinant human megakaryocyte growth and development factor
    • thrombopoietin
    • TPO
    • WBC
    • white blood cell

    ASJC Scopus subject areas

    • Cancer Research
    • Hematology
    • Oncology

    Cite this